Munger Mode rating: 3 out of 5 — Hold. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
A note on the price. My searches did not return a verified live quote for today. The most recent dated prints I found were about $264 (late September), about $250–251 (August–early September) and a 52-week range of roughly $191–$267. The market commentary after the October 30 report described about $250 as a possible new floor. I use $255 as the working price in this report. That is a round figure inside this range, not a quote. At that price, market capitalization is about $451 billion (1.768 billion shares). Check the actual quote before acting. A $20 move either way changes the margin of safety, though not the conclusion. AbbVie is the best-managed example I know of a company that got through a patent cliff. It lost exclusivity on Humira, once the world's best-selling drug, and revenue still reached a record.
Recent filings analysed: 10-Q (2026-11-03), 8-K (2026-11-02), 8-K (2026-10-30), 8-K (2026-10-15).
Stock screener · Superinvestor 13F holdings · Analyst sentiment